Table 9.
Efficacy and potency of pure cannabinoids and of most of their corresponding ‘botanical drug substance’ (BDS) as inhibitors of anandamide cellular uptake by RBL-2H3 cells
| Compounds | IC50 (µM) | Max concentration tested (% inhibition) |
|---|---|---|
| CBC | 12.3 ± 2.7 | 25 µM |
| 83.2 ± 3.5 | ||
| CBC-BDS | 15.7 ± 4.2 | 25 µM |
| 83.6 ± 7.8 | ||
| CBD | 25.3 ± 1.8 | 25 µM |
| 49.9 ± 1.3 | ||
| CBD-BDS | 11.5 ± 3.2 | 25 µM |
| 76.8 ± 5.3 | ||
| CBG | 11.3 ± 4.2 | 25 µM |
| 85.4 ± 0.8 | ||
| CBG-BDS | 14.2 ± 2.5 | 25 µM |
| 89.3 ± 2.7 | ||
| CBN | ∼25 | 25 µM |
| 50.0 ± 31.8 | ||
| CBDA | >25 | 25 µM |
| 36.3 ± 3.3 | ||
| CBDA-BDS | 5.8 ± 1.3 | 50 µM |
| 70.3 ± 2.4 | ||
| CBGA | >25 | 25 µM |
| 43.6 ± 5.0 | ||
| CBDV | 21.3 ± 1.8 | 25 µM |
| 52.7 ± 3.0 | ||
| CBDV-BDS | >25 | 25 µM |
| 16.4 ± 3.2 | ||
| CBGV | >25 | 25 µM |
| 31.2 ± 4.0 | ||
| CBGV-BDS | 6.9 ± 1.5 | 25 µM |
| 78.7 ± 21.3 | ||
| THCA | >25 | 25 µM |
| 34.4 ± 2.8 | ||
| THCA-BDS | 9.7 ± 1.6 | 25 µM |
| 90.0 ± 4.6 | ||
| THCV | >25 | 25 µM |
| 46.9 ± 2.0 | ||
| THCV-BDS | >25 | 25 µM |
| 49.3 ± 2.2 | ||
| THCVA | >25 | 25 µM |
| 47.2 ± 2.1 | ||
| THCVA-BDS | 12.5 ± 5.2 | 25 µM |
| 71.0 ± 8.3 |
Data are means ± SEM of at least n = 3 separate experiments in which various concentrations (1, 5, 10, 25 µM) of the pure compounds/BDS were incubated. Efficacy was calculated as % of uptake inhibition at the maximal concentration tested (25 µM).
CBC, cannabichromene; CBD, cannabidiol; CBDA, cannabidiol acid; CBDV, propyl analogue of CBD or cannabidivarin; CBG, cannabigerol; CBGV, cannabigivarin; CBN, cannabinol; THC, Δ9-tetrahydrocannabinol; THCA, THC acid; THCV, propyl analogue of THC or tetrahydrocannabivarin; THCVA, tetrahydrocannabivarin acid.